Sunday, 14 August 2022

 

 

LATEST NEWS Since 1917, Jharkhand's Tana Bhagats have been worshipping the Tricolour daily One thing that stands out is how Rohit Sharma backs players who aren't performing: Parthiv Patel Since 1917, Jharkhand's Tana Bhagats have been worshipping the Tricolour daily This drug can fight more than 300 drug-resistant bacteria Madonna Sebastian to appear opposite Tovino Thomas in 'Identity' Australia plans to increase migrant intake amid skill crisis A Rajasthan Royals owner slapped me three or four times, says Ross Taylor in his autobiography PM pays homage to all those who lost their lives during Partition Saumya Tandon urges fans to help late 'Bhabiji' star Deepesh Bhan's family repay loan No Olympic future for CWG lawn bowls 'trailblazers', squash players Honour freedom fighters by flying the National Flag, says Rajinikanth Vijay Sethupathi's team clarifies: Actor not a part of 'Pushpa 2' AAP's expanding its national presence at a rapid pace after Punjab victory Birmingham 2022 successes could mark the start of a new era in Indian athletics Simona Halep moves into Toronto final; set to enter Top-10 in latest WTA rankings For wife Mila Kunis, Ashton Kutcher with moustache was 'like a different guy' TOPS has given a different 'spin' to sports in India, says Mansher Singh India's Covid tally declines to 14,092 cases, 41 deaths 13 killed, 5 injured as truck falls over bus in Pakistan Elon Musk hopes for a self-sustaining city on Mars in 20 years Musk pitches lofty goals in magazine run by China's Internet censorship agency

 

Sanofi-GSK Covid vax shows strong immune responses in Phase 2 trial

Coronavirus, COVID 19, Novel Coronavirus, Fight Against Corona, Covaxin, Covishield, Covid-19 Vaccine, Oxygen, #OxygenCylinders, SARS-CoV-2, Sputnik V, Oxygen Plants, Pfizer, Astra Zeneca, Oxygen Concentrator, Remdesivir, Covifor, Oxygen supply, Liquid Medical Oxygen, Sanofi and Glaxo Smith Kline, GSK, Sanofi-GSK Covid vax

Web Admin

Web Admin

5 Dariya News

Paris , 18 May 2021

A Covid-19 vaccine developed by pharmaceutical giants Sanofi and Glaxo Smith Kline (GSK) has shown strong rates of neutralising antibody responses against the infectious Coronavirus disease in the Phase-II trial.The Phase-II trial, which involved 722 adult volunteers from the US and Honduras between 18 to 95 years old, did not raise any safety concerns and also produced a strong immune response across all age groups.It showed 95 per cent to 100 per cent seroconversion following a second injection, while a single jab produced high neutralising antibody levels among people with prior SARS-CoV-2 infection. This suggested the vaccine's strong potential for development as a booster shot.The vaccine also elicited strong neutralising antibody levels that were comparable to those generated by natural infection. The higher levels observed in people between 18 to 59 years old."Our Phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis, as we know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines, which can be stored at normal temperatures, increases," said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur, in a statement."These positive data show the potential of this protein-based adjuvanted vaccine candidate in the broader context of the pandemic, including the need to address variants and to provide for booster doses. We believe that this vaccine candidate can make a significant contribution to the ongoing fight against Covid-19," added Roger Connor, President of GSK Vaccines.In December, last year, the Sanofi-GSK faced a major setback after their experimental Covid-19 vaccine did not appear to work well in older adults.The pharma companies, now, aim to start a global pivotal Phase 3 study in the coming weeks. The Phase-III trial is expected to enroll more than 35,000 adult participants from a broad range of countries and will assess the efficacy of two vaccine formulations including the D614 (Wuhan) and B1351 (South African) variants.The French pharma company Sanofi and its British peer GSK aim to produce up to one billion doses in 2021.In addition, the companies also intend to conduct booster studies with various variant formulations in order to assess the ability of a lower dose of the vaccine to generate a strong booster response regardless of the initial vaccine platform received.

 

Tags: Coronavirus , COVID 19 , Novel Coronavirus , Fight Against Corona , Covaxin , Covishield , Covid-19 Vaccine , Oxygen , #OxygenCylinders , SARS-CoV-2 , Sputnik V , Oxygen Plants , Pfizer , Astra Zeneca , Oxygen Concentrator , Remdesivir , Covifor , Oxygen supply , Liquid Medical Oxygen , Sanofi and Glaxo Smith Kline , GSK , Sanofi-GSK Covid vax

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2022 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD